Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07013565 · ClinicalTrials.gov registry record · Phase 2
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
A Phase 2 study of Anaplastic Large Cell Lymphoma, ALK-Positive, sponsored by New York Medical College.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07013565 is a Phase 2 study of Anaplastic Large Cell Lymphoma, ALK-Positive that is active but no longer recruiting, run by New York Medical College. The registered enrollment target is 20 participants, below the 65-participant average among 4 other Anaplastic Large Cell Lymphoma, ALK-Positive trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07013565, a Phase 2 study of Anaplastic Large Cell Lymphoma, ALK-Positive, is active but no longer recruiting, sponsored by New York Medical College.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) high-risk ALK+ Anaplastic Large Cell Lymphoma (ALCL) have a low incidence of overall survival. This clinical trial will investigate if a new FDA approved medication called Nivolumab (NIVO) (which is a checkpoint blockade immunotherapy) combined with chemotherapy based on the patients risk status to get the patient into the best response possible. Then patients will receive lower doses of chemoimmunotherapy and allogeneic stem cell transplantation (stem cells from another person). The investigators this this new treatment will improve survival rates in this high-risk population of patients.
Conditions Studied
Interventions
- DRUG Vinblastine (Velban)
- DRUG Brentuximab vedotin (Adcetris)
- DRUG Nivolumab (Opdivo)
Study Locations (1)
New York
- New York Medical College - Valhalla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-08-07 |
| Est. Completion | 2030-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07013565
The ClinicalTrials.gov registry entry for NCT07013565 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 4 other Anaplastic Large Cell Lymphoma, ALK-Positive trials with a reported enrollment target (69% lower). The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anaplastic Large Cell Lymphoma, ALK-Positive appearing as the primary indexed condition, and to 3 interventions - of which Vinblastine (Velban) is the first listed.
NCT07013565 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07013565 about?
NCT07013565 is a clinical study titled "Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL". Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) high-risk ALK+ Anaplastic Large Cell Lymphoma (ALCL) have a low incidence of overall survival. This clinical trial will investigate if a new FDA approved medication called Nivolumab (NIVO) (which is a checkpoint blockade i...
What is the current status of trial NCT07013565?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-08-07. Estimated completion is 2030-07-01.
What conditions does trial NCT07013565 study?
This clinical trial studies the following conditions: Anaplastic Large Cell Lymphoma, ALK-Positive.
What interventions are being tested in trial NCT07013565?
The interventions under investigation include: Vinblastine (Velban) (DRUG), Brentuximab vedotin (Adcetris) (DRUG), Nivolumab (Opdivo) (DRUG).
Who is sponsoring clinical trial NCT07013565?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07013565 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anaplastic Large Cell Lymphoma, ALK-Positive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
ACTIVE NOT RECRUITING · Phase 2
-
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
RECRUITING · Phase 1
-
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.